BNF Section/s |
Title |
Issuing Body |
Date of Issue/Review |
Update Due |
1.5 |
Antispasmodics - Antispasmodics Position Statement - ( dicycloverine and propantheline ) |
Kent and Medway ICB |
Oct 2023 |
Oct 2025 |
1.8 |
Botulinum - Botulinum toxin for chronic anal fissures |
Kent & Medway PRGC |
May 2016 |
- |
1.11 |
Budesonide - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis TA708 |
NICE |
Jun 2021 |
- |
1.2.2 |
Constipation - Guidance on Constipation |
MFT/Medway & Swale CCG |
Jan 2020 |
Jan 2022
|
1.1.3 |
Etrasimod (Velsipity®) ICB commissioned - approval via Blueteq |
High-Cost Drugs |
|
|
1.1.3 |
Etrasimod - Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over TA956 |
NICE |
Mar 2024 |
- |
1.5 |
Hyoscine butylbromide - Misuse of Hyoscine butylbromide |
NHSPHE |
Jun 2015 |
- |
1.1 |
Inflammatory Bowel Disease - Inflammatory Bowel Disease(IBD) (Adults) High Cost Drug Pathway Version 1.14 |
Kent and Medway ICB |
Jun 2023 |
Jun 2025 |
1.1 |
Inflammatory Bowel Disease - Dual biological therapy for inflammatory bowel disease (IBD) in adults |
Kent & Medway PRGC |
Sep 2022 |
- |
1.3 & 1.1.3 |
Infliximab biosimilar - Flixabi® ICB commissioned - approval via Blueteq - (Diarrhoea and colitis relating to ICPI therapy 1.3)
|
High-Cost Drugs |
|
|
1.1.3 |
Infliximab biosimilar - Flixabi® - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy TA329 ICB commissioned - approval via Blueteq (Adults)
|
NICE |
Feb 2015 |
- |
1.1.3 |
Infliximab biosimilar - Flixabi®- Infliximab and adalimumab for the treatment of Crohn's disease TA187 ICB commissioned - approval via Blueteq (Adults) NHSE commissioned - (Paediatrics 6 - 17) -
|
NICE |
May 2010 |
- |
1.1.4 |
Linaclotide - Linaclotide for irritable bowel syndrome with constipation |
Kent & Medway PRGC |
Jul 2019 |
- |
1.1.3 |
Mirikizumab -(Omvoh®) |
High-Cost Drugs |
|
|
1.1.3 |
Mirikizumab - Mirikizumab for treating moderately to severely active ulcerative colitis TA925 |
NICE |
Oct 2023 |
- |
1.2.2.5 |
Naldemedine - Naldemedine for treating opioid-induced constipation TA651 |
NICE |
Sep 2020 |
2023 |
1.2.2.5 |
Naloxegol - Naloxegol for treating opioid‑induced constipation TA345 |
NICE |
Jul 2018 |
- |
1.7 |
Obesity - Obesity prevention CG43 |
NICE |
Mar 2015 |
- |
1.4.5 |
Omeprazole - Omeprazole Oral suspension for Paediatrics in Primary Care– Position Statement
|
Kent and Medway ICB |
Dec 2023 |
Dec 2025 |
1.1.3
|
Ozanimod
|
High-Cost Drugs |
|
|
1.1.3
|
Ozanimod - Ozanimod for treating moderately to severely active ulcerative colitis TA828 ICB commissioned - approval via Blueteq
|
NICE |
Oct 2022 |
- |
1.4.5
|
PPI - Proton Pump Inhibitor Oral suspension for Adults Primary Care – Position Statement |
Kent and Medway ICB |
Dec 2023 |
Dec 2025 |
1.1.3 |
Risankizumab
|
High-Cost Drugs |
|
|
1.1.3 |
Risankizumab - Risankizumab for previously treated moderately to severely active Crohn's disease TA888 ICB commissioned - approval via Blueteq (Adults) NHSE commissioned - (Adolescents 16 - 17)
|
NICE |
May 2023 |
- |
1.1.3 |
Upadacitinib
|
High-Cost Drugs |
|
|
1.1.3
|
Upadacitinib - Upadacitinib for previously treated moderately to severely active Crohn’s disease TA905
|
NICE |
Jun 2023 |
|
1.1.3
|
Upadacitinib - Upadacitinib for treating moderately to severely active ulcerative colitis TA856 |
NICE |
Jan 2023 |
|
1.7
(6.3.1.4)
|
Wegovy - Information about Wegovy (Semaglutide) for Obesity |
Kent and Medway ICB |
Mar 2023 |
|
1.7
|
Wegovy - Semaglutide for managing overweight and obesity TA875 |
NICE |
Sep 2023 |
- |